Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands

Here's your US approval and review news in brief: FDA cleared two novel antibiotics on the eve of the Infectious Disease Society of America’s “ID Week” meeting in San Francisco Oct. 3-7.

With approval for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections on Oct. 2, Paratek Pharmaceuticals Inc.’s broad-spectrum Nuzyra (omadacycline) became the third novel antibiotic approved in 2018 with FDA’s Qualified Infectious Disease Product (QIDP) designation. TetraPhase Pharmaceuticals Inc